Here, we present all evidence on omega-3 fatty acids and polar lipids on their bioactivities against Cardiovascular Diseases (CVD).
N-3 fatty acids do NOT reduce the cardiovascular risk! In our latest paper (in review: Marine Drugs), we explain why N-3 fatty acids are NOT effective and we discuss the value of Polar Lipids.
Omega-3 studies are using 4000mg/day and yet there is no decrease in the cardiovascular risk.
It is safe to say that polar lipids are the food components with strong potential against CVD and hence our work in UL focuses further to this class of lipids.
It is clear from the wealth of evidence presented that understanding the mechanisms of PAF/PAF-R signalling in health and disease has yet to be fully elucidated. However, the discovery of various PAF and PAFLL agonists and antagonists, the role of the PAF metabolic enzymes in diseases, solving the human PAF-R structure, and identifying PAF signalling mechanisms independent of the PAF-R are some of the many major achievements in current PAF research. PAF is clearly linked to inflammation and CVD.
However, we might need to wonder if omega 3 PUFAs are actually active against CardioVascular Diseases (CVD). The answer to that question is simple: NO! You can find more info on this, here.